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Yu-Zhu Wang, Gao-Lin Liu and Xiao-Yu Li*
Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,
China
Non-alcoholic fatty liver disease (NAFLD) is a prevalent liver disease associated with
lipotoxicity, lipid peroxidation, oxidative stress, and inflammation. Nuciferine, an active
ingredient extracted from the natural lotus leaf, has been reported to be effective for the
prevention and treatment of NAFLD. Per-Arnt-Sim kinase (PASK) is a nutrient responsive
protein kinase that regulates lipid and glucose metabolism, mitochondrial respiration,
and gene expression. The aim of the present study was to investigate the protective
effect of nuciferine against NAFLD and its inhibitory effect on PASK, exploring the
possible underlying mechanism of nuciferine-mediated inhibition on NAFLD. Relevant
biochemical parameters (lipid accumulation, extent of oxidative stress and release of
inflammation cytokines) in oleic acid (OA)-induced HepG2 cells that mimicked steatosis
in vitro were measured and compared with the control. It was found that nuciferine
and silenced-PASK (siRNA PASK) both inhibited triglyceride (TG) accumulation and was
effective in decreasing fatty acid (FFAs). The content of total antioxidant capacity (T-AOC)
and superoxide dismutase (SOD) were increased respectively by nuciferine and siRNA
PASK without increase in glutathione (GSH). Malondialdehyde (MDA) was decreased
respectively by nuciferine and siRNA PASK. In addition, nuciferine decreased TNF-a,
IL-6 and IL-8 as well as the siRNA PASK group. IL-10 was increased by nuciferine and
siRNA PASK respectively. Further investigation revealed that nuciferine and siRNA PASK
could respectively regulate the expression of target genes involved in lipogenesis and
inflammation, suggesting that nuciferine may be a potential therapeutic treatment for
NAFLD. Furthermore, the modulated effect of nuciferine on (OA)-induced HepG2 cells
lipogenesis and inflammation, which was accompanied with PASK inhibition, was also
consistent with siRNA PASK, implying that PASK might play a role in nuciferine-mediated
regulation on NAFLD.
Keywords: nuciferine, Per-Arnt-Sim kinase, non-alcoholic fatty liver disease, hepatic lipid accumulation,
inflammation
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a chronic disorder
characterized by hepatic steatosis without signiﬁcant alcohol
consumption. NAFLD, which is believed to be associated
with central obesity, dyslipidemia, hypertension, hyperglycemia,
and other metabolic disorders (Tarantino et al., 2007), is
accompanied with a cluster of clinic manifestations ranging from
benign hepatocellular steatosis, inﬂammatory non-alcoholic
steatohepatitis (NASH) and ﬁbrosis to cirrhosis. According
to the theory “two hits” hypothesis proposed by Day and
James (1998), the pathogenesis of NAFLD is intricate. The
ﬁrst “hit” is deposition of free fatty acid and triglyceride in
hepatocytes (steatosis), and the second “hit” is the progression
of steatosis to NASH. Both progresses are accompanied with
the stimulation of hepatic lipogenesis and the release of
inﬂammation cytokines, which are the main causes of NAFLD.
Therefore, several therapeutic targets have been investigated for
the treatment of NAFLD, including the important mediators
and nutrient sensors of cellular lipid and glucose homeostasis—
AMP-activated protein kinase (AMPK; Dahlhoﬀ et al., 2014)
and peroxisome proliferator-activated receptor (PPARα/γ) (Zhao
et al., 2014).
Similarly, Per-Arnt-Sim kinase (PASK), a nutrient responsive
protein kinase, is an emerging regulator in lipid and glucose
metabolism (Hao and Rutter, 2008; Grose and Rutter, 2010).
PASK is a canonical serine/threonine kinase that contains PAS
domain and can eﬀectively regulate lipid and glucosemetabolism,
mitochondrial respiration, phosphorylation and gene expression
(Schlaﬂi et al., 2009; Cardon and Rutter, 2012). Hao et al. (2007)
found that the metabolic rate and mitochondrial respiration
were both increased in PASK knockdown mice (PASK−/−) fed
with high-fat diets, and this increase was also accompanied with
the increased performance of hyperactive metabolism and ATP
production. To a large extent, PASK−/− could be successfully
protected from obesity, implying that PASK may participate
in lipogenesis and metabolism and therefore may be a new
therapeutic target for the treatment of metabolic diseases and
disorders such as NAFLD.
Although various medications have been developed to
improve NAFLD (Vidyashankar et al., 2013; Hwang et al.,
2014; Zhang et al., 2015b), their adverse eﬀects prevent them
from being more widely applied in clinical practice. Therefore,
researchers have gradually focused their attention on natural
products. Nuciferine is a major active ingredient extracted from
the lotus leaf and has been shown to have a wide spectrum
of pharmacological activities, including relaxing the smooth
muscle, ameliorating hyperlipidemia, dilating vessels, preventing
arrhythmia, stimulating insulin secretion, and reducing body
weight (Luo et al., 2005; Ma et al., 2010; Nguyen et al.,
2012). Currently, Guo et al. (2013) reported that high-fat diet-
induced liver steatosis and injury in hamsters were signiﬁcantly
suppressed by nuciferine supplementation, indicating that
nuciferine may be used as a possible remedy for NAFLD.
However, the speciﬁc mechanism remains unclear. Under
such circumstances, our present study aimed at exploring the
protective eﬀect of nuciferine against NAFLD and its possible
underlying mechanism. HepG2 cells (Mersch-Sundermann et al.,
2004) was selected in this study, they retain and mimic
many of the specialized functions, which characterize normal
human hepatocytes and used extensively to study the phase
I, phase II and antioxidant enzymes ensuring that they
constitute a good model to study cytoprotective, genotoxic,
and antigenotoxic eﬀects of compounds in vitro (Cui et al.,
2010; Vidyashankar et al., 2013). Whereas, treatment with oleic
acid (OA) (Araya et al., 2004) would induce morphological
similarities to steatotic hepatocytes. Therefore, we established
a cellular model of HepG2 cells treated with OA to mimic
hepatic steatosis in vitro and explore the possible mechanism of
nuciferine in attenuating lipid accumulation and inﬂammation.
Meanwhile, based on our previous hypothesis that PASK
may participant in inﬂammation (Zhang et al., 2015a), we
silenced PASK (siRNA PASK) in HepG2 cells to test the
possible functions and mechanism of PASK inhibition on lipid
accumulation and inﬂammation paralleled with evaluation of
nuciferine. In addition, according to human epidemiological
study, vitamin E administration has been reported to be
superior to placebo for the treatment of NASH in adults
(Sanyal et al., 2010; Pacana and Sanyal, 2012), hence, we
selected Vitamin E as our positive control paralleled with
evaluation of nuciferine and siRNA PASK. The results showed
that the stimulation of hepatic lipogenesis and the release
of inﬂammation cytokines could be eﬀectively reversed by
nuciferine in OA-induced HepG2 cells, which was apparently
consistent with the results in siRNA PASK HepG2 cells.
More importantly, nuciferine could signiﬁcantly decrease the
expression of PASK, and even the relevant targets genes of
PASK also showed similar trends as the alteration in siRNA
PASK HepG2 cells. Therefore, we speculate that nuciferine and
PASK could both potently modulate hepatic lipogenesis and
inﬂammation and PASKmight play a role in nuciferine-mediated
regulation.
MATERIALS AND METHODS
Materials
Cell culture medium DMEM (Gibco, USA), FBS (Gibco,
European), and the antibodies (PASK, sterol regulatory element-
binding protein-1c (SREBP-1c), AMPK, phospho-AMP activated
protein kinase (pAMPK), nuclear factor kappa-B (NF-κB) were
purchased from Abcam (USA). Oil-red-O, OA, vitamin E and
nuciferine were obtained from Sigma–Aldrich (USA). Ethanol
(99%), DMSO and other chemicals were purchased from Sigma–
Aldrich (USA).
Cell Culture
The human hepatocellular carcinoma cell line HepG2 was
purchased from the Type Culture Collection of the Chinese
Academy of Sciences (Shanghai, China). HepG2 cells were
cultured with high glucose DMEM containing 10% FBS and 0.5%
penicillin-streptomycin in an incubator in an atmosphere of 5%
CO2 at 37◦C with 95% humidity.
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Cytotoxicity
HepG2 cells were seeded in a 96-well plate at 5× 103 cells/well for
24 h, and then treated with various concentrations (0–500 μM)
of nuciferine (dissolved by DMSO) and OA (40 μM) according
to the Cell Counting kit-8 assay (CCK8) of a range of OA (0–
1 mM, dissolved by ethanol). After 24 h incubation, absorbance
readings at 490 nm were obtained using a spectrophotometer
(Thermo Varioskan). Cell viability was calculated as follows:
Cell viability = (Anuciferine + OA – Ablank)/(ADMSO + ethanol –
Ablank) × 100%, using HepG2 cells without both OA and
nuciferine as control.
Cell Apoptosis
Cells treated with nuciferine (10, 25, and 50 μM) were
stained with PE Annexin V and 7-Amino-Actinomycin (7-
AAD) following the manufacturer’s instructions to detect early
apoptotic cells (PEAnnexinV+7-AADevents) and late apoptotic
cells (PE Annexin V+7-AAD events). HepG2 cells without both
OA and nuciferine were selected as control and all groups were
examined by ﬂow cytometry (BD Accuri C6).
OA-induced Steatosis
Oleic acid was selected to induce cellular steatosis in HepG2 cells
as previously described (Araya et al., 2004; Vidyashankar et al.,
2013; Hwang et al., 2014). HepG2 cells seeded in a 6-well plate at
6-well plate 5 × 105 cells/well, cultured for 24 h, and then added
with the medium containing diﬀerent concentrations of OA (40,
80, 120, 160, and 200μM) for another 24 h. The medium without
OA but containing BSAwas selected as the control. The optimum
dosage was evaluated by both oil-red-o staining and cell viability
of each concentration.
Staining Using Oil-Red-O
After incubation of HepG2 cells (5 × 105 cells/well) with BSA
medium containing OA (40, 80, 120, 160, and 200 μM), or
cultured with BSA-OA (40 μM) medium complex with or
without nuciferine and the positive control vitamin E (25 μM)
for 24 h, cells were washed with PBS three times and ﬁxed in
4% paraformaldehyde at room temperature for 40 min. After
removing the ﬁxative, cells were washed with PBS three times,
stained with a freshly prepared working solution (3:2) of oil-
red-O, and incubated for 15 min at room temperature. After
removing the oil-red-O working solution, cells were washed with
PBS ﬁve times, and ﬁnally observed under a microscope. Similar
methods were used in siRNA PASK cells incubated with BSA-
OA for 24h. The staining extent of oil-red-O was quantitated
with Image-Pro Plus 6.0. The mean optical density (MOD) was
calculated as follows: MOD = IOD/SUM Area.
The Inhibitory Effect of Nuciferine or
siRNA PASK on OA-induced Hepatic
Steatosis, Inflammation and Oxidative
Stress
Based on the optimal dosage of OA (40 μM) according to
experiments as described earlier, HepG2 cells (5 × 105 cells/well)
were incubated with BSA-OA (40 μM) complex with or without
nuciferine, and PASK-silenced (siRNA PASK) HepG2 cells were
treated with BSA-OA (40μM)medium, using vitamin E (25μM)
as the positive control, HepG2 cells without both OA and
nuciferine as control and siRNA PASK HepG2 cells without OA
as siRNA scrambled. After 24 h treatment, cell culture medium
and cell protein supernatants were harvested and kept at −80◦C
for quantiﬁcation of several parameters.
Measurement of Lipid Accumulation
The extent of lipid accumulation was measured by TG from cell
protein supernatants and the Fatty acid (FFAs) concentration
from cell culture medium. Both of them were quantitated by
commercially available enzyme linked immunosorbant assay
(ELISA) following the user guide (CUSABIA, China).
Measurement of Inflammatory Cytokines
The evaluation of inﬂammation cytokine including TNF-α, IL-8,
IL-6, and IL-10 in the cultured medium were assayed using an
ELISA kit according to the manufacturer’s instructions.
Measurement of Oxidative Stress
Oxidative stress was measured with the level of glutathione
(GSH), the content of total antioxidant capacity (T-AOC) and
superoxide dismutase (SOD) from cell protein supernatants. All
of them were assayed using the ELISA kit according to the
manufacturer’s protocol.
Measurement of Lipid Peroxidation
The level of Malondialdehyde (MDA) from cell cultured serum
was related to lipid peroxidation which was quantitated by ELISA.
Western Blots Analyses
Cells treated with nuciferine or siRNA PASK HepG2 cells
were lysed with lysis buﬀer (150 nM sodium chloride, 1%
Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 50 nM Tris-HCl, and 2 mM ethylenediamine tetra-acetic
acid) on ice for 45 min. After centrifugation at 12000 rpm
at 4◦C for 15 min, the supernatant was collected, and
the protein concentration was determined by BSA method.
Equal amounts were separated by sodium dodecyl sulfate
polyacrylamid Gel electrophoresis (SDS-PAGE) and electro-
transferred onto polyvinylidene diﬂuoride (PVDF) membranes,
which were then blocked with 5% bovine serum albumin
(BSA) and probed with primary antibodies against PASK,
SREBP-1c, AMPK, p-AMPK, NF-κB at 4◦C overnight, washed
with 1% TBST (TBS containing 1% Tween-20) three times
before incubation in alkaline phosphatase-conjugated secondary
antibody for 1.5 h at room temperature. After three washes,
the chemiluminescence signal was imaged using a ChemiDoc
XRS (Bio-Rad) and quantitated using Quantity One software
(Bio-Rad).
Real-Time Quantitative Reverse
Transcription-PCR Analyses (RT-qPCR)
Total RNA of cells treated with nuciferine or siRNA PASKHepG2
cells were extracted by using Trizol (Invitrogen) and veriﬁed by
electrophoresis. The mRNA was reverse-transcribed into cDNA
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with a reverse-transcription kit (Thermo Fisher Scientiﬁc). The
Primer sequences listed in Table 1 used for PCR were from
Sangon, Biotech. SYBR Green I (Amersco) was added into the
reaction mixture. RT-qPCR was performed on an MJ Opticon 2
thermal cycler (MJ Research Inc.) following the manufacturer’s
instruction.
Immunostaining
Cells treated with nuciferine or siRNA PASK HepG2 cells were
washed three times with PBS, ﬁxed in 4% paraformaldehyde at
37◦C for 20 min, permeabilized in 0.5% Triton-X for 15 min,
and blocked in 5% goat serum for 1 h. After incubation with
the appropriate primary (overnight incubation at 4◦C) and
secondary (2 h at 37◦C) antibodies, the cells were imaged using
a confocal laser scanning microscope (Leica TCS SP8).
PASK Silencing
HepG2 cells were transfected with human PASK-speciﬁc
siRNAs (Oobio) using transfection reagent (Oobio) according
to the method of Wu et al. (2014). SiRNA sequence:
GCTGATGGAAAGCCAAGACAT.
Statistical Analysis
The results are described asmean± SEM from three independent
experiments. Statistical signiﬁcances were tested by the ANOVA
and the Student’s t-test. Data analysis was carried out using
GraphPad Prism version 6 (GraphPad Software). P-values below
0.05 were considered statistically signiﬁcant.
RESULTS
OA-induced TG Accumulation in HepG2
Cells
To mimic the hepatic steatosis in vitro, HepG2 cells were
treated with 0–200 μM concentrations of OA for 24 h to
induce TG steatosis. The optimal concentration depended on
the cytotoxic eﬀect of OA and the TG content evaluated
by oil-red-O staining. Compare to the control (HepG2 cells
without OA), the cell viability value ranged from 52 to 91%
(Figure 1A) (∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001)
while the recovered oil-red-O content (determined by MOD)
was increased signiﬁcantly (Figures 1B,C) (∗∗P < 0.01 and
∗∗∗P < 0.001). Cell viability values greater than 90% were
considered the unaﬀected concentration combined with the
increased TG content. Therefore, 40 μM OA was selected as the
ﬁnal concentration to induce TG accumulation.
Cytotoxicity and Apoptosis of Nuciferine
To eliminate any misinterpretation owing to cell apoptosis
or death caused by toxicity of nuciferine, apoptosis, and
cytotoxicity on HepG2 cells were assessed. Cells were treated
with the OA (40 μM) and 0–500 μM nuciferine for 24 h. The
cytotoxic eﬀect of nuciferine was determined by cell viability.
Compare to the control (HepG2 cells without both OA and
nuciferine), the value ranged from 57 to 91% at 0–500 μM
concentrations and values greater than 85% were considered
unaﬀected concentrations (∗∗∗P < 0.001 vs. control). Therefore,
10 μM, 25 μM, and 50 μM nuciferine concentrations were
used to reduce fatty liver (Figure 2A). In addition, nuciferine
concentrations ranging from 10 to 50 μM did not signiﬁcantly
induce apoptosis of HepG2 cells according to ﬂow cytometric
analysis (Figure 2B).
The Effect of Nuciferine or siRNA PASK
on TG Accumulation in OA-induced
Hepatic Steatosis
To examine the catabatic role of nuciferine and silenced PASK
in TG accumulation, any decrease in TG content was evaluated
using the ELISA kit and oil-red-O staining. Owing to the results
of all parameters in the control group were almost consistent
with the siRNA scrambled (data were not shown), for more
concise, we selected siRNA scrambled as control in our next
results. It was found that TG accumulated in OA treated
cells as compared with the control (∗∗∗P < 0.001). The three
concentrations of nuciferine decreased TG accumulation by 16.6,
33.7, and 52.7% respectively (∗∗P < 0.01 and ∗∗∗P < 0.001
vs. OA), while vitamin E (25 μM) and siRNA PASK reduced
the TG content by 38.6% (∗∗P < 0.01 vs. OA) and 53%
TABLE 1 | Sequences of primers.
Gene Forward Primer (5′-3′) Reverse Primer (5′-3′) Size
β-actin AGCGAGCATCCCCCAAAGTT GGGCACGAAGGCTCATCATT 285bp
SREBP-1c TGGCTGCTCAATGGGCTGTT GCGATGCCTCCAGAAGTACACG 136bp
PPAR-γ GGAGGTCCGCATCTTTCACT GCTACCAGCATCCCGTCTTT 195bp
PPAR-α CTGGTAGCGTATGGAAATG AAATGATAGCAGCCACAAA 160bp
TNF-α TCAGAGGGCCTGTACCTCAT GGAAGACCCCTCCCAGATAG 220bp
NF-κB CACTTAGCAATCATCCACCTT GCAAATCCTCCACCACATCTT 163bp
SCD1 CCCAGCTGTCAAAGAGAAG CAAGAAAGTGGCAACGAACA 187bp
PASK AGCTGAAATCCCAACCCA CTCCGTCTTTCCGTAACCA 185bp
AMPK GTGACCTCAAGCCTTCCAAC TTTCTGGAGCCCTGTACCAA 150bp
Akt GCACCTTCCATGTGGAGACT CCCAGCAGCTTCAGGTACTC 214bp
ACC CATGCGGTCTATCCGTAGGT TGTTGTTGTTTGGTCCTCCA 158bp
FAS TGCCAAGAAGGGAAGGAG TGGTGTTGCTGGTGAGTG 238bp
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FIGURE 1 | Oleic acid-induced TG accumulation in HepG2 cells. (A) The Dose dependent effect of OA (40, 80, 120, 160, and 200 μM) on cytotoxicity in
HepG2 cells. (B,C) The effect of OA (40, 80, 120, 160, and 200 μM) on TG accumulation in HepG2 cells. Original magnification was 200×, scale bars represent
75 μm. Values are Mean ± SEM of three independent experiments performed in triplicates. Statistically significant at ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001
compared with the control.
FIGURE 2 | Cytotoxicity and apoptosis of nuciferine. (A) Cytotoxicity of nuciferine in HepG2 cells. HepG2 cells were incubated with OA (40 μM) and increased
concentrations of nuciferine (10, 25, 50, 100, 250, and 500 μM) for 24 h, and cell viability was measured by CCK8 assay. (B) The dose dependent effect of
nuciferine (10, 25, and 50 μM) on cell apoptosis in HepG2 cells. Values are Mean ± SEM of three independent experiments performed in triplicates. Statistically
significant at ∗∗∗P < 0.001 compared with the control.
(∗∗∗P < 0.001 vs. OA) respectively as compared with OA group
(Figure 3A). Microscopic examination using oil-red-O staining
showed that lipid droplets in cells treated with 10, 25, and
50 μM nuciferine decreased by 15, 45.5, and 60.7% respectively
as determined by MOD (∗∗∗P < 0.001 vs. OA), 54.6% for 25 μM
vitamin E (∗∗∗P < 0.001 vs. OA) and 63% for siRNA PASK
(∗∗∗P< 0.001 vs. OA) as compared with OA group (∗∗∗P< 0.001
vs. control) (Figures 3B,C). These data initially imply that both
nuciferine and siRNA PASK had a regulatory eﬀect on lipid
accumulation.
Frontiers in Pharmacology | www.frontiersin.org 5 October 2015 | Volume 6 | Article 238
Zhang et al. Nuciferine and PASK alleviate NAFLD
FIGURE 3 | The effect of nuciferine or siRNA PASK on TG accumulation in HepG2 cells of OA-induced hepatic steatosis. (A) TG concentration tested by
ELISA. (B,C) Oil-red-O staining. Original magnification was 200×, scale bars represent 75 μm. SiRNA PASK HepG2 cells and HepG2 cells incubated with increasing
concentrations of nuciferine (NF: 10, 25, and 50 μM) or vitamin E (25 μM) both treated with OA (40 μM). The measurement was described in the Section “Materials
and Methods”. Values are Mean ± SEM of three independent experiments performed in triplicates. Significant differences with OA group were designated as
∗∗P < 0.01 and ∗∗∗P < 0.001. (Control, siRNA scrambled; NF, Nuciferine.)
The Effect of Nuciferine or siRNA PASK
on Cell Lipotoxicity in OA-induced
Hepatic Steatosis
To further explore the regulatory eﬀect of nuciferine on lipid
accumulation, the lipotoxicity caused by a cluster of FFAs that
induced hepatic steatosis was measured. The addition of OA
resulted in a 2.57-fold increase in FFAs as compared with the
control (∗∗∗P< 0.001). The increased concentration of nuciferine
decreased the FFAs level by 18.66, 39 and 44.01% respectively
(∗∗P < 0.01 vs. OA), while vitamin E (25 μM) and siRNA PASK
inhibited cellular FFAs by 42.81% (∗∗P < 0.01 vs. OA) and
50.22% (∗∗∗P < 0.001 vs. OA) respectively as compared with OA
group (Figure 4). These data indicate that nuciferine and siRNA
PASK played a regulatory role in attenuating lipid accumulation,
similarly.
The Effect of Nuciferine or siRNA PASK
on the Expression of Lipogenic Genes
Related to Hepatic Steatosis
To decipher the possible mechanism underlying the nuciferine-
mediated eﬀect on lipogenesis, nine important genes involved in
lipogenesis were evaluated. According to results of the mRNA
expression by RT-qPCR, the expression of PASK, SREBP-1c, fatty
acid synthase (FAS), acetyl-CoA (ACC), stearoyl-CoA desaturase
1 1 (SCD1), PPAR-α and PPAR-γ was increased in OA-treated
cells compared with the control (∗P < 0.05 and ∗∗∗P < 0.001),
and this increase could be signiﬁcantly reversed by nuciferine (10,
25, and 50μM) and siRNA PASK.Meanwhile, the level of AMPK
and protein kinase B (Akt) showed signiﬁcantly decreased in OA-
induced HepG2 cells (∗∗P < 0.01 and ∗∗∗P < 0.001), and they
both increased when treated with nuciferine and siRNA PASK
(∗P< 0.05, ∗∗P< 0.01, and ∗∗∗P< 0.001 vs. OA) (Figures 5A,B).
These ﬁndings demonstrate that nuciferine could attenuate lipid
accumulation by regulating the expression of relevant target
genes involved in lipogenesis, which was accompanied with
downregulated expression of PASK and was consistent with
alterations of relevant genes in siRNA PASK group.
The Effect of Nuciferine or siRNA PASK
on the Expression of Proteins Related to
Hepatic Steatosis
To further characterize the downregulation of PASK mediated
by nuciferine, western blot analysis of HepG2 cells from
Frontiers in Pharmacology | www.frontiersin.org 6 October 2015 | Volume 6 | Article 238
Zhang et al. Nuciferine and PASK alleviate NAFLD
FIGURE 4 | The effect of nuciferine or siRNA PASK on cell lipotoxicity
in HepG2 cells of OA-induced hepatic steatosis. SiRNA PASK HepG2
cells and HepG2 cells incubated with increased concentrations of nuciferine
(NF: 10, 25, and 50 μM) or vitamin E (25 μM) both treated with OA (40 μM).
The measurement was described in the Section “Materials and Methods”.
Values are Mean ± SEM of three independent experiments performed in
triplicates. Significant differences with OA group were designated as
∗∗P < 0.01 and ∗∗∗P < 0.001. (Control, siRNA scrambled; NF, Nuciferine.)
the experimental samples was conducted. It was found
that the expression of PASK (∗∗∗P < 0.001) and SREBP-1c
(∗∗∗P < 0.001) was increased in OA group compared with
the control, while the level of PASK incubated with nuciferine
(10, 25, and 50 μM, ∗∗P < 0.01 and ∗∗∗P < 0.001 vs. OA)
and siRNA PASK (∗∗∗P < 0.001 vs. OA) was decreased
compared with OA group. Similar results were obtained for
SREBP-1c expression (∗∗P < 0.01 and ∗∗∗P < 0.001 vs. OA).
Meanwhile, the expression of AMPK was decreased in OA
group compared with control (∗∗∗P < 0.001 vs. control), and
signiﬁcantly increased in nuciferine (∗∗∗P < 0.001 vs. OA) and
siRNA PASK groups (∗∗∗P < 0.001 vs. OA) (Figures 6A,B).
Similar consequences were obtained in immunostaining assay
(Figure 6E). In addition, to further evaluate the activation of
AMPK, we have also measured the p-AMPK with p-AMPK
antibody by western blot, ﬁnding that treatment of OA
(∗∗∗P < 0.001 vs. control) downregulated the expression
of p-AMPK, and this decreased level could be reversed by
nuciferine and siRNA PASK (∗∗∗P < 0.001 vs. OA) (Figure 6C).
Meanwhile, similar trend were emerged in the ratio of
p-AMPK/AMPK (p-AMPK∗GAPDH(A)/GAPDH(p)∗AMPK)
(∗P < 0.05) (Figure 6D), indicating that nuciferine could
upregulate both the expression and activation of AMPK in
OA-induced HepG2 cells. These results imply that nuciferine
could regulate the expression of PASK, AMPK, SREBP-1c
and relevant target genes during its inhibition of excessive
lipogenesis.
The Effect of Nuciferine or siRNA PASK
on Cell Lipid Peroxidation and Oxidative
Stress in OA-induced Hepatic Steatosis
To see whether nuciferine or siRNA PASK could ameliorate lipid
peroxidation and oxidative stress, the main factors contributed
to NASH, we tested the content of GSH, T-AOC and SOD,
which were selected as measurement of lipid peroxidation. The
GSH level in OA group was signiﬁcantly depleted compared
with the control (∗∗P < 0.01). Upon addition of nuciferine,
the content of GSH was surprising decreased by 13.51, 46.66
and 49% (∗P < 0.05 vs. OA), and siRNA PASK depleted
by 69.97% (∗P < 0.05 vs. OA), but vitamin E signiﬁcantly
increased GSH level by twofold compared with the OA group
(∗∗∗P < 0.001 vs. OA) (Figure 7A). The T-AOC and SOD
level in OA group was signiﬁcantly depleted compared with
the control (∗P < 0.05 and ∗∗P < 0.01), and addition of
nuciferine could simultaneously reverse the decrease level of
T-AOC (∗∗∗P < 0.001 vs. OA) and SOD (∗P < 0.05 vs. OA),
while the siRNA PASK (∗∗∗P < 0.001 and ∗P < 0.05 vs. OA)
and vitamin E (∗∗∗P < 0.001 vs. OA) showed similar trend
(Figures 7B,C). In addition, MDA was regarded as measurement
of oxidative stress. The OA treated group could signiﬁcantly
increase MDA content compared with the control (∗∗∗P< 0.001).
Addition of nuciferine diminishedMDA level by 33.57, 34.07 and
34.12 (∗∗P < 0.01 vs. OA), and vitamin E (25 μM) and siRNA
PASK were inhibited by 27.62% (∗∗P < 0.01 vs. OA) and 35%
(∗∗P < 0.01 vs. OA) compared with the OA group (Figure 7D).
These ﬁndings demonstrate that nuciferine and siRNA PASK
could both successfully decrease the oxidative stress, probably
owing to the down-regulation of antioxidant molecules SOD,
T-AOC, but not GSH.
The Effect of Nuciferine or siRNA PASK
on Inflammatory Cytokines in
OA-induced Hepatic Steatosis
To clarify the possible role of nuciferine or siRNA PASK on
inﬂammation, inﬂammatory cytokine levels were observed in
OA induced HepG2 cells. It was found that the concentration
of TNF-α increased by 2.3-fold (∗∗∗P < 0.001), IL-6 by 4.84-
fold (∗∗∗P < 0.001), and IL-8 by 4.35-fold (∗∗∗P < 0.001)
in OA-induced HepG2 cells as compared with the control.
Nuciferine (10, 25, and 50 μM) decreased the level of TNF-
α by 41.39, 43.45, and 44.57% (∗∗∗P < 0.001 vs. OA), IL-
6 by 38.66, 70.53, and 76.53% (∗∗∗P < 0.001 vs. OA), and
IL-8 by 67.31, 75.33, and 76.04% respectively (∗∗∗P < 0.001
vs. OA), while vitamin E and siRNA PASK also reverted the
TNF-α increase by 40.84% (∗∗∗P < 0.001 vs. OA) and 51.08%
(∗∗∗P < 0. 001 vs. OA), IL-6 by 67.08% (∗∗∗P < 0.001 vs.
OA) and 83.29% (∗∗∗P < 0.001 vs. OA), and IL-8 by 67.41%
(∗∗∗P < 0.001 vs. OA) and 85.2% (∗∗∗P < 0.001 vs. OA)
compared with OA group (Figures 8A–C). In addition, IL-10
in OA treated cells was inhibited by 68.09% compared with
the control (∗∗P < 0.01). Addition of nuciferine (10, 25, and
50 μM) increased the level of IL-10 by 2, 1.96, and 1.65-fold
respectively (∗P < 0.05 vs. OA). Likewise, siRNA PASK and
vitamin E (25 μM) improved the IL-10 by 1.24-fold (∗P < 0.05
vs. OA) and fourfold (∗∗∗P < 0.001 vs. OA) respectively
compared with OA treated group (Figure 8D). These results
imply that nuciferine and siRNA PASK may play a potential
role in preventing and attenuating the process of inﬂammation,
similarly.
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FIGURE 5 | (A,B) The effect of nuciferine or siRNA PASK on lipogenic genes related to hepatic steatosis in HepG2 cells. SiRNA PASK HepG2 cells and HepG2 cells
incubated with increased concentrations of nuciferine (NF: 10, 25, and 50 μM) both treated with OA (40 μM). The measurement was described in the Section
“Materials and Methods”. Values are Mean ± SEM of three independent experiments performed in triplicates. Significant differences with OA group were designated
as ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. (Control, siRNA scrambled; NF, Nuciferine.)
The Effect of Nuciferine or siRNA PASK
on the Expression of Genes and Proteins
Related to Inflammation
To further deliberate the possible mechanism underlying the
nuciferine-mediated eﬀect on inﬂammation, the alteration of
genes involved in release of inﬂammatory cytokines was
measured. The expression of TNF-α (∗P < 0.05) and NF-κB
(∗∗∗P < 0.001) mRNA in HepG2 cells treated with OA was
increased signiﬁcantly as compared with that in the control.
Meanwhile, siRNA PASK could signiﬁcantly inhibited the level
of TNF-α (∗P < 0.05 vs. OA) and NF-κB (∗∗∗P < 0.001 vs.
OA) mRNA compared with the OA-treated cells. However,
addition of nuciferine (10, 25, and 50μM) showed no statistically
signiﬁcant decrease in expression of TNF-α mRNA though it
could signiﬁcantly downregulate the NF-κB mRNA expression
(∗∗∗P < 0.001 vs. OA) (Figure 9A). In addition, the expression
of NF-κB (∗∗∗P < 0.001 vs. control) in HepG2 cells treated
with OA was upregulated signiﬁcantly as compared with the
control, and this upregulation could be successfully reverted by
nuciferine (10, 25, and 50 μM; ∗∗∗P < 0.001 vs. OA) and siRNA
PASK (∗∗∗P < 0.001 vs. OA) (Figures 9B,C). These data suggest
that inhibition of TNF-α and NF-κB might be the potential
mechanism underlying the regulatory eﬀect of nuciferine on
inﬂammation, which was accompanied with downregulated
expression of PASK.
DISCUSSION
Non-alcoholic fatty liver disease is often considered as the hepatic
manifestation of the metabolic syndrome (MS) accompanied
with a cluster of metabolic disorders including obesity, insulin
resistance (IR), hypertension, and dyslipidemia (Tarantino et al.,
2007). It is reported that approximate 80–90% obese adults in
the western world suﬀer from NAFLD (Lazo and Clark, 2008;
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FIGURE 6 | The effect of nuciferine or siRNA PASK on the expression of proteins related to hepatic steatosis in HepG2 cells. (A–C) Western blot for
PASK, SREBP-1c, AMPK, and p-AMPK. (D) The ratio of pAMPK/AMPK (p-AMPK∗GAPDH(A)/GAPDH(p)∗AMPK). (E) Immunostaining for PASK, SREBP-1c and
AMPK (red) and the nuclear dye DAPI (blue), scale bars represent 25 μm. SiRNA PASK HepG2 cells and HepG2 cells incubated with increasing concentrations of
nuciferine (NF: 10, 25, and 50 μM) both treated with OA (40 μM). The measurement was described in the Section “Materials and Methods”. Values are Mean ± SEM
of three independent experiments performed in triplicates. Significant differences with OA group were designated as ∗∗P < 0.01 and ∗∗∗P < 0.001. (Control, siRNA
scrambled; NF, Nuciferine.)
Bellentani et al., 2010). Currently, pervasive researches have been
made to explore the eﬀective therapy for NAFLD (Salamone et al.,
2012b; Takahashi et al., 2015). Unlike vitamin E or other lipid-
lowering drugs, nuciferine is an active ingredient extracted from
the natural product lotus leaf (Xu et al., 2007). It is reported
that nuciferine can exert a protective eﬀect against liver steatosis
and inﬂammation in vivo (Guo et al., 2013). As an emerging
therapeutic agent for liver diseases, we speculate that nuciferine
is a potential drug lead for the treatment of NAFLD.
As the mechanism underlying the regulatory eﬀect of
nuciferine on NAFLD remains uncertain, our studies used
OA induced-HepG2 cells to establish liver steatosis models
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FIGURE 7 | The effect of nuciferine or siRNA PASK on cell lipid peroxidation in HepG2 cells of OA-induced hepatic steatosis. (A) GSH. (B) T-AOC.
(C) SOD. (D) MDA. SiRNA PASK HepG2 cells and HepG2 cells incubated with increased concentrations of nuciferine (NF: 10, 25, and 50 μM) or vitamin E (25 μM)
both treated with OA (40 μM). The measurement was described in the Section “Materials and Methods”. Values are Mean ± SEM of three independent experiments
performed in triplicates. Significant differences with OA group were designated as ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. (Control, siRNA scrambled; NF,
Nuciferine.)
in an attempt to explore the speciﬁc mechanism in vitro
(Figure 1). It was found in our study that the concentration
of FFAs was increased signiﬁcantly in OA-induced HepG2 cells
(Figure 4), which resulted in lipotoxicity, increased TG content,
lipid peroxidation, oxidative stress, and increased generation of
inﬂammatory cytokines.
Per-Arnt-Sim kinase, as an emerging regulator on mammalian
glucose and lipid metabolism, possesses a biological activity in the
regulation of MS, and may exert a potential and pivotal impact
on drug therapy of NAFLD. However, the eﬀect mediated by
PASK on NAFLD, especially on NASH, remains unknown. Thus,
we silenced PASK in HepG2 cells and found that inhibition of
PASK could reverse the events caused NAFLD/NASH, which was
simultaneously evaluated along with nuciferine and vitamin E.
As a typical characteristic in the ﬁrst stage of NAFLD, excessive
stimulation (Ahmed et al., 2015) of hepatic lipogenesis resulted
from the increased inﬂux of FFAs into hepatocytes is a crucial risk
factor leading to deterioration of NAFLD. Hence, attenuating
or preventing hepatic lipogenesis is of great importance in
treating NAFLD Guo et al. (2013) measured the concentration
of TG and FFAs of hepatic tissue extracted from high-fat diet
induced hamsters and found that nuciferine had a downregulated
eﬀect on lipid accumulation. Similarly, as shown in our study
(Figures 3 and 4), nuciferine also involved in inhibition of
lipid accumulation, independently and signiﬁcantly reversing
the concentration of TG and FFAs in OA-treated HepG2 cells
without any other internal factors, which could eliminate other
uncertain factors contributing to the catabatic role of nuciferine
in decreasing hepatic lipid accumulation. Meanwhile, there was a
decreased tendency of FFAs and TG in OA-treated siRNA PASK
HepG2 cells, suggesting that PASK may involve in regulation
of hepatic lipid accumulation, decreasing excessive lipogenesis.
In addition, vitamin E was not as eﬀective as nuciferine in
reversing the biochemical parameters, although it also inhibited
the stimulation of hepatic lipogenesis.
It has been proved that PASK is required for the proteolytic
maturation of the SREBP-1c, and administration of a PASK
inhibitor could downregulate hepatic expression of lipogenic
SREBP-1c and its target genes, enhancemitochondrial respiration
through upregulating the expression of AMPK pathway, decrease
serum triglycerides, and partially reverse IR (Hao et al., 2007; Wu
et al., 2014). Under such circumstances, to further decipher the
possible mechanism of nuciferine that Guo et al. (2013) did not
accomplish, we focused on PASK and evaluated the expression of
lipogenesis-related genes including SREBP-1c, FAS, ACC, SCD1,
lipid-responsive nuclear hormone receptor (PPARα and PPARγ)
and further observe the alterations of two relevant target genes
of PASK (AMPK and Akt) in nuciferine and siRNA PASK group.
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FIGURE 8 | The effect of nuciferine or siRNA PASK on inflammatory cytokines in HepG2 cells of OA-induced hepatic steatosis. (A) TNF-α. (B) IL-6.
(C) IL-8. (D) IL-10. SiRNA PASK HepG2 cells and HepG2 cells incubated with increased concentrations of nuciferine (NF: 10, 25, and 50 μM) or vitamin E (25 μM)
both treated with OA (40 μM). The measurement was described in the Section “Materials and Methods”. Values are Mean ± SEM of three independent experiments
performed in triplicates. Significant differences with OA group were designated as ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001. (Control, siRNA scrambled; NF,
Nuciferine.)
Interestingly, nuciferine decreased the expression of PASK and
its relevant target genes PPARα, PPARγ, SREBP-1c, FAS, ACC,
and SCD1, and upregulated the expression and activation of
AMPK that regulates the mitochondrial respiration and lipid
metabolism. In addition, the same alternations were observed
in OA-treated siRNA PASK HepG2 cells (Figure 5), indicating
that PASK participated in lipid metabolism, and therefore PASK
might be a potential therapeutic target for ameliorating hepatic
lipid accumulation, and even could be an eﬀective treatment
for NAFLD and other MS accompanied with lipid accumulation
or obesity. More importantly, as compared with similar eﬀects
of PASK inhibition and nuciferine on alleviating lipogenesis,
nuciferine could also downregulate the PASK expression and
alter the level of relevant genes of PASK. Hence, our ﬁnding
suggest for the ﬁrst time that PASK-mediated inhibition of lipid
accumulation may be a potential mechanism of nuciferine in
alleviating NAFLD probably by regulating the expression of
PASK, AMPK, SREBP-1c, and relevant targets genes (Figure 6).
However, further studies are required to clarify whether the
mediation of PASK on eﬀect of nuciferine is predominant or
dispensable.
Interestingly, we found an increased expression of Akt in
nuciferine-treated steatotic cells and OA-treated siRNA PASK
HepG2 cells compared with the depleted level in OA-induced
HepG2 cells (Figure 5). The PI3K/Akt pathway is known to
promote GLUT4 expression in myocytes and adipocytes (Bryant
et al., 2002), and the activation of Akt may be an essential
requirement for ameliorating IR, a typical characteristic of
NAFLD/NASH (Vidyashankar et al., 2013; Hojlund, 2014). In
accordance with earlier ﬁndings that nuciferine (Nguyen et al.,
2012; Guo et al., 2013) and PASK (Fontes et al., 2009; Sabatini
and Lynn, 2015) could eﬀectively attenuate IR, our result found
a increased expression of Akt in OA-treated cells incubated with
nuciferine and siRNA PASK HepG2 cells, suggesting that PASK
may play an important role in IR, and PASK inhibition might
be part of mechanism of the nuciferine-mediated regulative
eﬀect on IR. However, further investigations are required to
independently deliberate the speciﬁc mechanism of PASK in
nuciferine-mediated treatment of IR.
Increased FFAs inﬂux into HepG2 cells may cause severe
lipotoxicity, leading to an imbalance between pro-oxidants
and antioxidants (Abdul-Ghani et al., 2008), which is likely
to increase the generation of reactive oxygen species (ROS)
and MDA (Nourazarian et al., 2014) that induce a series of
cellular damage (Hoﬀman and Brookes, 2009). Earlier studies
(Guo et al., 2013) had proved that nuciferine could decrease
the MDA in high-fat diet induced hamsters, but the cause
remains inconclusive. Furthermore, whether PASK contributed
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FIGURE 9 | (A) The effect of nuciferine or siRNA PASK on the mRNA level related to inflammation in HepG2 cells. (B,C) The effect of nuciferine and siRNA PASK on
the expression of proteins related to inflammation in HepG2 cells. SiRNA PASK HepG2 cells and HepG2 cells incubated with increased concentrations of nuciferine
(NF: 10, 25, and 50 μM) both treated with OA (40 μM). The measurement was described in the Section “Materials and Methods”. Values are Mean ± SEM of three
independent experiments performed in triplicates. Significant differences with OA group were designated as those ∗P < 0.05 and ∗∗∗P < 0.001. (Control, siRNA
scrambled; NF, Nuciferine.)
to the reversed concentration of MDA mediated by nuciferine
also remained unknown. Therefore, we similarly tested the
increases of ROS-mediated lipid peroxidation by measuring the
concentration of MDA from cell medium. It was found that the
elevated MDA level induced by OA was signiﬁcantly reversed
by nuciferine administration in OA-treated HepG2 cells and
OA-treated siRNA PASK cells (Figure 7D). Although vitamin E
also showed the similar eﬀect, it was not eﬀective as nuciferine,
conﬁrming that nuciferine could attenuate lipid peroxidation
by decreasing the concentration of MDA, which may be
partly related to the downregulated expression of PASK. More
importantly, our ﬁndings also ﬁrst proved that PASK potentially
plays a regulative role in mammalian [not yeast (Huang et al.,
2014)] lipid peroxidation and oxidative stress, which may provide
a reference for future research on physiological function of PASK.
Oxidative stress is caused by an imbalance in the redox
status of the body (Nourazarian et al., 2014). Thus, maintaining
the balance between pro-oxidant and antioxidant molecules
is imperative to downregulate ROS level. As an antioxidant
molecule, GSH plays a pivotal role in defending against ROS
(Kedderis, 1996). Studies (Guo et al., 2013) have shown that
nuciferine could downregulate the GSH in vivo. Surprisingly,
our result showed that the depleted GSH levels in OA-induced
group were not replenished in nuciferine treated OA-HepG2 cells
and the OA-treated siRNA PASK HepG2 cells, while the level
of GSH in vitamin E showed signiﬁcant increased (Figure 7A).
Although the reason is unknown, we speculate that the regulation
on GSH in vivo may be due to other participants such as
regulative enzymes or receptors but may not directly result from
nuciferine. Meantime, the results also imply that PASK exerted
no positive impact on GSH when the level of GSH in OA-treated
siRNA PASK HepG2 cells was signiﬁcantly decreased. However,
the concentration of T-AOC (Wang et al., 2015a) and SOD
(Kwon et al., 2012) were reversed by nuciferine and siRNA PASK
respectively as well as vitamin E (Figures 7B,C), demonstrating
that nuciferine could successfully decrease the oxidative stress
probably owing to the down-regulation of antioxidant molecules
SOD and T-AOC but not GSH, which was accompanied
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with the decreased expression of PASK. These results suggest
that the inhibition of PASK may play an imperative role in
downregulating oxidative stress controlled by nuciferine based
on the similar results from nuciferine and siRNA PASK groups.
Further comprehensive investigation on PASK participants in the
regulation of pro-oxidants and antioxidants is required.
Besides accumulation of lipogenesis, lipotoxicity, lipid
peroxidation, and oxidative stress, inﬂammation is another
crucial factor in the pathogenesis of NAFLD that aggravates the
progression from hepatocellular steatosis to NASH (Donath,
2013; Ahmed et al., 2015). Several previous studies (Guo
et al., 2013; Wang et al., 2015b) indicated that nuciferine
may be potential for the prevention and treatment of kidney
inﬂammation or liver inﬂammation, but the mechanism is
indeterminate. Thus, to determine the function of nuciferine
on the release of inﬂammatory cytokines, we evaluated the
TNF-α (Lin et al., 2015), IL-6 (Mykhal’chyshyn et al., 2013)
in similar lines with earlier ﬁndings, and further observed
the alterations of IL-8 and IL-10 (Burger, 2013; Fetahu
et al., 2014). The results obtained in our study showed that
TNF-α, IL-6 and IL-8 secretion were signiﬁcantly increased by
addition of OA paralleled with depleted IL-10 level. In contrast,
decreased levels were observed when OA-induced HepG2 cells
were incubated with nuciferine and vitamin E, and the IL-10
level showed signiﬁcantly increased. These results further show
that nuciferine could inhibit inﬂammation through blocking
the release of TNF-α, IL-6 and IL-8 and promoting the IL-
10 level. In addition, there is no evidence of a pronounced
relationship between PASK and inﬂammation. To explore the
possible eﬀect of PASK on inﬂammation and the potential role
of PASK in the nuciferine-mediated anti-inﬂammatory eﬀect,
we examined the alterations of TNF-α, IL-6, IL-8, and IL-
10 in OA-induced siRNA PASK HepG2 cells in similar lines
with nuciferine. Interestingly, the reversed eﬀect of TNF-α,
IL-6, IL-8, and IL-10 emerged in OA-induced siRNA PASK
HepG2 cells, as well as in nuciferine and vitamin E (Figure 8).
These ﬁndings demonstrate for the ﬁrst time that PASK could
eﬃciently attenuate inﬂammation by blocking the release of
inﬂammation cytokines, suggesting that PASK might emerge
as a new drug target for inﬂammation such as NASH due to its
anti-inﬂammatory eﬀect, which was consistent with eﬀects of
nuciferine. In addition, it was reported that the NF-κB pathway
(Okamoto et al., 2007) played an important role in contributing
to the NAFLD pathogenic process, and may be a possible target
for alleviation of NASH (Salamone et al., 2012a). Therefore, we
evaluated the alterations of NF-κB and TNF-α on gene and
protein levels in order to decipher the possible mechanism of
siRNA PASK and nuciferine mediated anti-inﬂammation. It was
found that OA treatment signiﬁcantly elevated the expression
of NF-κB and TNF-α in the liver. However, treatment with
nuciferine or vitamin E blocked OA-induced expression of
NF-κB and TNF-α, which is consistent with the results in
OA-induced siRNA PASK HepG2 cells (Figure 9). Therefore,
according to the results that both nuciferine and siRNA PASK
could alleviate inﬂammation by preventing the release of
inﬂammation cytokines such as TNF-α, IL-6, and IL-8, and
nuciferine could downregulate the expression of PASK, TNF-
α, and NF-κB, which was similar to the alteration in siRNA
PASK group, taken together, we speculate the inhibition of PASK
may be predominate or part of the mechanism underlying the
anti-inﬂammation function of nuciferine. These ﬁndings may
be preliminary, and our future research will further address the
speciﬁc role of PASK in nuciferine-mediated anti-inﬂammatory
eﬀect.
CONCLUSION
Our results demonstrate that nuciferine possesses potent
function on attenuating or inhibiting lipid accumulation and
inﬂammation and regulates the expression of PASK and
its relevant target genes involved in lipid metabolism and
inﬂammation in OA-induced HepG2 cells, indicating that
nuciferine and PASK have a potential inhibitory eﬀect against
NAFLD/NASH, and the PASK might play an important role in
nuciferine-mediated regulation. Our future investigations will be
dedicated to additional in vivo work.
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